ReviewExpert review of vaccines2017
Pneumococcal whole-cell and protein-based vaccines: changing the paradigm.
Review in Expert review of vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Pooled it
- ZPY-CpG-Ch, a broad coverage vaccine againstScience advances · 2026Article
- What is driving the resurgence and persistence of vaccine-targeted pneumococcal serotypes?-Serotype 19F as the paradigm.PLoS pathogens · 2026Review
- Review
- Recent developments of vaccines for older adults: Adjuvants and beyond.Human vaccines & immunotherapeutics · 2025Review
- The Complex Landscape of Updated Pneumococcal Conjugate Vaccines.Open forum infectious diseases · 2025Article
- Post-vaccination Streptococcus pneumoniae colonization and respiratory manifestations in children: A prospective cohort study.PloS one · 2025Observational
- Streptococcus pneumoniae serotype distribution in Bangladeshi under-fives with community-acquired pneumonia pre-10-valent pneumococcal conjugate vaccination.Pneumonia (Nathan Qld.) · 2024Article
- Article
- Convergent impact of vaccination and antibiotic pressures on pneumococcal populations.Cell chemical biology · 2024Review
- A brief history of and future prospects for pneumococcal vaccination in Malaysia.Pneumonia (Nathan Qld.) · 2023Review
- IL-27 mediates immune response of pneumococcal vaccine SPY1 through Th17 and memory CD4iScience · 2023Article
- Prevalence and Homology of the Pneumococcal Serine-Rich Repeat Protein at the Global Scale.Microbiology spectrum · 2023Article
- Strengths and weaknesses of pneumococcal conjugate vaccines.Glycoconjugate journal · 2023Review
- Influence of the mRNA initial region on protein production: a case study using recombinant detoxified pneumolysin as a model.Frontiers in bioengineering and biotechnology · 2023Article
- Peptide linker increased the stability of pneumococcal fusion protein vaccine candidate.Frontiers in bioengineering and biotechnology · 2023Article
- A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.Biomedicines · 2022Review
- Targeted Transcriptomic Screen of Pneumococcal Genes Expressed during Murine and Human Infection.Infection and immunity · 2022Article
- Molecular Epidemiology of Multidrug-Resistant Pneumococci among Ghanaian Children under Five Years Post PCV13 Using MLST.Microorganisms · 2022Article
- Immune Memory After Respiratory Infection WithFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
introductionEpidemiologic evaluations of Streptococcus pneumoniae nasopharyngeal (NP) colonization and pneumococcal disease suggest that newer serotypes in future formulations of pneumococcal conjugate vaccines (PCVs) are needed and there may need to be continued reformulations because there are many new emerging serotypes expressed by pneumococci. Areas covered: Mechanisms of protection by next-generation whole-cell vaccine (WCV) and/or multi-component pneumococcal purified protein vaccines (PPVs) in development for prevention of pneumococcal infections. Expert commentary: A long-term strategy for prevention of pneumococcal disease will likely include WCV and PPVs. However these vaccines will impact disease pathogenesis in a different manner than PCVs. Prevention of pneumococcal NP colonization should not be expected, nor is it desirable because risks for NP colonization by other replacement organisms into the ecological niche vacated by all pneumococci may have consequences. The expression biology of capsule and surface protein antigens are phase dependent. Therefore, the immune response will be different and the mechanism of protection divergent. WCVs and PPVs may be alternative strategies in low income developing countries to protect against invasive disease and reduce NP carriage load.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.